A leading lawmaker is intensifying his scrutiny of the financial ties between opioid makers, advocacy groups, and government panels that provide advice on the controversial and lucrative business of managing patient pain.

In a letter to the Department of Health and Human Services, Sen. Ron Wyden (D-Ore.) asked the agency to review various conflicts of interest among some members of the Pain Management Best Practices Inter-Agency Task Force, which was created two years ago to make recommendations for combating chronic and acute pain. Those directives may affect Medicare and Medicaid reimbursements.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy